Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC2-01 topical formulations in plaque psoriasis
2013-005003-14Phase 2Completed
- Sponsor
- Catalent
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of calcipotriol + betamethasone, betamethasone dipropionate and calcipotriol in plaque psoriasis (5 arms), sponsored by Catalent. Primary endpoints: Efficacy of MC2-01 formulations and Safety of MC2-01 formulations. Started Jan 2014; status: completed.
02
Drugs
calcipotriol + betamethasonebetamethasone dipropionatecalcipotriol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2013-005003-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005003-14.